Pharmacogenomics and Precision Immunosuppression in Kidney Transplantation: Where Do We Stand?
Year: 2025
Type: article
Abstract: Calcineurin inhibitors (CNIs) remain central to immunosuppressive strategies in kidney transplantation and underpin the substantial improvements in graft and patient survival achieved over the past four decades. The introduction of cyclosporine in the early 1980s marked a pivotal shift in transplant outcomes, transforming rejection from an expected event into a manageable complication.[1] However, this success has always been accompanied by a persistent clinical challenge: a narrow therapeutic window in which small variations in drug exposure may result in rejection at one extreme and toxicity, most notably nephrotoxicity, at the other. As transplant medicine increasingly moves toward precision-based approaches, the question is no longer whether CNIs work, but how best to individualize their use. In this context, pharmacogenomics has emerged as a promising tool, but where do we stand in translating this promise into meaningful clinical benefit? Both cyclosporine and tacrolimus exert their immunosuppressive effects by inhibiting calcineurin-dependent T-cell activation, leading to suppression of interleukin-2 production in CD4⁺ T cells. This suppression occurs in a concentration-dependent manner and remains inversely correlated with circulating drug levels. Consequently, calcineurin inhibition lies at the fulcrum of a delicate therapeutic balance, where even modest fluctuations in exposure may translate into inadequate immunosuppression or drug-related toxicity. This narrow margin explains why therapeutic drug monitoring remains an essential component of routine posttransplant management. The pharmacokinetic complexity of CNIs is most evident with tacrolimus, whose metabolism is predominantly mediated by the cytochrome P450 enzyme CYP3A5. At the molecular level, CYP3A5 expression is regulated by alternative splicing driven by genetic variation within the CYP3A5 gene on chromosome 7q21.1.[2] The most clinically relevant polymorphism, A6986G (rs776746), located in intron 3, creates an aberrant splice site during pre-mRNA processing. This leads to the insertion of a 131-base pair pseudo-exon, resulting in a frameshift and premature termination of translation. Consequently, individuals homozygous for the CYP3A5*3 allele produce little or no functional CYP3A5 enzyme. In contrast, carriers of the functional CYP3A5*1 allele undergo normal splicing and express an intact 502-amino acid enzyme. This results in increased hepatic and intestinal CYP3A5 activity, enhanced first-pass metabolism of tacrolimus, and higher dose requirements to achieve target trough concentrations. The contribution of intestinal CYP3A5 expression further amplifies interindividual variability in tacrolimus exposure.[3] Importantly, the population distribution of CYP3A5 alleles varies substantially, contributing to ethnic differences in dose requirements; CYP3A5 (*3/*3) nonexpressors are observed in up to 85% of the Caucasian population, in contrast to the African population with much lesser frequency.[4] These differences have important clinical implications. A uniform initial tacrolimus dose (e.g., 0.2 mg/kg/day) may result in excessive exposure in CYP3A5 nonexpressors, increasing the risk of nephrotoxicity, delayed or slow graft function, and neurotoxic manifestations such as tremors, seizures, or psychosis. This variability provided a strong rationale for pharmacogenomics-guided dosing strategies aimed at optimizing early tacrolimus exposure and minimizing toxicity. Beyond hepatic metabolism, drug transport mechanisms further contribute to tacrolimus pharmacokinetic variability. The ABCB1 (MDR1) gene encodes P-glycoprotein (P-gp), an ATP-dependent efflux transporter expressed in the intestinal epithelium, hepatocytes, renal tubular cells, and the luminal surface of brain capillary endothelium. By regulating tacrolimus absorption, tissue distribution, and elimination, P-gp plays a critical role in systemic drug exposure and drug–drug interactions. Polymorphisms within ABCB1, together with interindividual differences in CYP3A4/5 expression, add further complexity to CNI disposition.[5] In the era of precision medicine, these mechanistic insights have prompted multiple clinical trials evaluating genotype-guided tacrolimus dosing. While some studies have demonstrated no meaningful difference between genotype-based and conventional body weight-based dosing,[6] others have shown earlier attainment of target trough concentrations with CYP3A5-guided strategies.[7] Population pharmacokinetic models incorporating clinical variables (albumin, creatinine, and hematocrit), demographic factors (age and body surface area), and genetic data have further refined individualized starting doses, enabling a greater proportion of patients to achieve therapeutic concentrations earlier after transplantation.[8] However, whether these pharmacokinetic advantages translate into improved clinical outcomes remains uncertain. Studies assessing hard endpoints, including rejection, delayed graft function, graft survival, and patient survival, have not consistently demonstrated benefit from genotype-guided dosing strategies.[9] Adverse events such as nephrotoxicity, neurotoxicity, and delayed graft function have been observed even after achieving predefined target tacrolimus concentrations. Despite recommendations from expert groups such as the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group, genotype-based dosing has not convincingly altered long-term outcomes. This apparent disconnect likely reflects limitations of whole-blood tacrolimus trough concentrations (C0 Tac) as a surrogate for biologically relevant exposure.[10] In clinical practice, patients may develop toxicity despite therapeutic trough levels, whereas others tolerate supratherapeutic concentrations without adverse effects. Several studies have demonstrated poor correlation between whole-blood tacrolimus concentrations and intrarenal or intralymphocytic drug levels. Tacrolimus exhibits marked compartmentalization, with approximately 85% residing within red blood cells, 14% in plasma, and only about 1% within lymphocytes, the primary target cells for immunosuppression.[11] In addition, intrapatient variability (IPV), which has been more consistently associated with rejection and graft loss, does not appear to be directly influenced by CYP3A5 genotype.[12] Another important phenotypic determinant is the trough concentration-to-dose (C0/D) ratio, which may more accurately identify fast metabolizers and predict nephrotoxicity risk. While CYP3A51 is associated with higher dose requirements at a population level, genotype does not uniformly translate into a fast-metabolizer phenotype at the individual level. Some CYP3A5 expressers achieve target concentrations with standard dosing, likely reflecting the influence of additional genetic modifiers (e.g., CYP3A422), drug–drug interactions, and clinical factors. These observations may explain why phenotypic markers such as the C0/D ratio correlate more closely with long-term outcomes than genotype alone.[13] Taken together, current evidence indicates that pharmacogenomics, particularly CYP3A5 genotyping, has enhanced our understanding of tacrolimus pharmacokinetic variability and can facilitate earlier achievement of target drug concentrations. The crucial takeaways from the existing literature evidence are, when applied in isolation, genotype-guided dosing has not consistently translated into improved graft or patient outcomes, underscoring the limitations of relying solely on genetic information or whole-blood trough levels. Second, phenotypic markers such as the C0/D ratio and IPV appear to better capture biologically relevant exposure and long-term risk. In this context, the recent systematic review by Oliveira provides a comprehensive synthesis of the available evidence, reinforcing both the promise and the current limitations of pharmacogenomic-guided immunosuppression.[14] Precision immunosuppression in kidney transplantation, therefore, is unlikely to be defined by a single genetic test; rather, it will require an integrated approach that combines pharmacogenomic insights with phenotypic measures, clinical context, and a deeper understanding of tissue-level drug exposure.
Authors: Vamsidhar Veeranki, Narayan Prasad
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7117244636